{"meta":{"query_hash":"60af21122bd7","filters":{"venue":"Journal of Bioequivalence & Bioavailability"},"cohort_total":8,"direct_labels_cover":0,"predictions_cover":8,"exported":8,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/60af21122bd7","api":"https://metacan.xera.ac/api/v1/cohort?venue=Journal+of+Bioequivalence+%26+Bioavailability"},"results":[{"id":"W2117943248","doi":"10.4172/jbb.1000113","title":"Comparative Bioavailability: Two Pramipexole Formulations in Healthy Volunteers after a Single Dose Administration under Fasting Conditions","year":2012,"lang":"en","type":"article","venue":"Journal of Bioequivalence & Bioavailability","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bioavailability; Pramipexole; Pharmacology; Medicine; Pharmacokinetics; Internal medicine; Parkinson's disease; Disease","score_opus":0.1465024108902202,"score_gpt":0.4379382427566109,"score_spread":0.2914358318663907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117943248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961333,0.0011787117,0.00084210734,0.000055705506,0.000099871664,0.00059588935,0.00034789142,0.00005020699,0.0006963657],"genre_scores_gemma":[0.9902344,0.0014013174,0.002716885,0.00020937742,0.00021183096,0.0013583362,0.0007376601,0.000024390441,0.0031059075],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99948055,0.00015456548,0.00003732905,0.0001705508,0.00010474124,0.00005237539],"domain_scores_gemma":[0.99947816,0.00012724963,0.00009690848,0.000080591584,0.0001108037,0.00010638586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001201877,0.0007275212,0.0016189682,0.0003375822,0.0005240696,0.00046261327,0.0002735831,0.0011244515,0.0030167156],"category_scores_gemma":[0.0012222602,0.00048660362,0.00051912694,0.00027883344,0.00063909945,0.0005479935,0.00027071522,0.00094726746,0.00078003923],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40702945,0.030015653,0.0068477048,0.00092094677,0.00045009598,0.00078940607,0.0010225251,0.0004505029,0.5011055,0.00026174518,0.0012313492,0.04987514],"study_design_scores_gemma":[0.019278,0.8038963,0.08299247,0.000037388207,0.00090683775,0.0014680988,0.00042896892,0.0016700857,0.084776655,0.0002664616,0.0041825175,0.000096116186],"about_ca_topic_score_codex":0.0006160464,"about_ca_topic_score_gemma":0.0006663812,"teacher_disagreement_score":0.0030167156,"about_ca_system_score_codex":0.00023504077,"about_ca_system_score_gemma":0.0004171024,"threshold_uncertainty_score":0.010091901},"labels":[],"label_agreement":null},{"id":"W2519144724","doi":"","title":"Biosimilars? pricing policies in Canada: A new challenge to provincial governments","year":2013,"lang":"en","type":"article","venue":"Journal of Bioequivalence & Bioavailability","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Business; Medicine; Internal medicine","score_opus":0.024892823770357595,"score_gpt":0.2675882434322147,"score_spread":0.24269541966185712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519144724","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033729035,0.005762863,0.00092082075,0.923797,0.0011013154,0.00009624233,0.0013548433,0.00014030554,0.033097558],"genre_scores_gemma":[0.61024094,0.012670818,0.008569903,0.30067003,0.0014268686,0.0001126212,0.0011892386,0.0003019425,0.0648177],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98235184,0.0015362931,0.00059703423,0.00095692335,0.008478167,0.0060797045],"domain_scores_gemma":[0.94078475,0.0073897564,0.0024431364,0.0008549199,0.027169038,0.02135839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010250314,0.00041056512,0.001151981,0.0025605762,0.012213442,0.014867183,0.004639434,0.010996651,0.013813125],"category_scores_gemma":[0.030855557,0.0009212826,0.0013168807,0.0056009516,0.004930706,0.004448156,0.0027638872,0.010753337,0.00084228633],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00031842457,0.00033365373,0.029823016,0.00051072513,0.00017731111,0.0006798076,0.0032454578,0.0032392552,0.0017023905,0.18397595,0.66950387,0.10649016],"study_design_scores_gemma":[0.00036579883,0.00012974875,0.0877942,0.0014005002,0.00019523807,0.00027725886,0.008750085,0.0071695833,0.00095114653,0.03967187,0.8528411,0.0004535838],"about_ca_topic_score_codex":0.992661,"about_ca_topic_score_gemma":0.99573743,"teacher_disagreement_score":0.79241055,"about_ca_system_score_codex":0.20758945,"about_ca_system_score_gemma":0.5606069,"threshold_uncertainty_score":0.91908395},"labels":[],"label_agreement":null},{"id":"W2519942097","doi":"","title":"Targeting cancer stem cells: Challenges and opportunities","year":2013,"lang":"en","type":"article","venue":"Journal of Bioequivalence & Bioavailability","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dasatinib; Imatinib; Stem cell; Progenitor cell; Cancer research; Cancer stem cell; Medicine; Tyrosine kinase; Myeloid leukemia; CD34; Haematopoiesis; Chronic myelogenous leukemia; Tyrosine-kinase inhibitor; Population; Immunology; Cancer; Leukemia; Biology; Internal medicine; Cell biology; Receptor","score_opus":0.08584506014930933,"score_gpt":0.295643831768893,"score_spread":0.20979877161958366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519942097","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009456518,0.5781622,0.0063665197,0.24486607,0.009950695,0.00015646579,0.0009642957,0.00048430575,0.14959295],"genre_scores_gemma":[0.05995359,0.6914658,0.008046137,0.03570081,0.003912029,0.00018860446,0.000999609,0.00018485001,0.19954851],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991365,0.000065187014,0.00002485892,0.000100892496,0.00045108856,0.00022147389],"domain_scores_gemma":[0.99667394,0.0002804442,0.00007337666,0.00009246321,0.0016814684,0.0011983217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018787787,0.0006154651,0.0007733362,0.0010320442,0.0017910644,0.003553497,0.001195158,0.0025726038,0.030075902],"category_scores_gemma":[0.0017192813,0.00029697464,0.000246856,0.001092191,0.0025718415,0.0014625229,0.0018336095,0.003506578,0.00651665],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020416015,0.00009643884,0.0011092075,0.0012775699,0.000018809622,0.0004929808,0.0003628723,0.0004955356,0.011000034,0.03764976,0.4703867,0.47690597],"study_design_scores_gemma":[0.000019378813,0.00005469124,0.00084166287,0.0004832169,0.00001002954,0.00025440694,0.00030119627,0.00025092126,0.0018287033,0.005565764,0.9903685,0.000021601914],"about_ca_topic_score_codex":0.18005219,"about_ca_topic_score_gemma":0.34489703,"teacher_disagreement_score":0.18005219,"about_ca_system_score_codex":0.011012668,"about_ca_system_score_gemma":0.021985298,"threshold_uncertainty_score":0.35800833},"labels":[],"label_agreement":null},{"id":"W2522289024","doi":"","title":"Regulatory consideration of the assessment of biosimilar products","year":2013,"lang":"en","type":"article","venue":"Journal of Bioequivalence & Bioavailability","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Harmonization; Scope (computer science); Interchangeability; Risk analysis (engineering); Business; Product (mathematics); Order (exchange); Bioequivalence; Medicine; Biotechnology; Pharmacology; Computer science; Finance; Pharmacokinetics","score_opus":0.023726712127593898,"score_gpt":0.2906560368767194,"score_spread":0.2669293247491255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522289024","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04987418,0.14740697,0.115735404,0.18786477,0.022246372,0.0047001406,0.0023543895,0.0015472096,0.46827054],"genre_scores_gemma":[0.5835955,0.06831435,0.1425575,0.12753573,0.014330241,0.0045300624,0.0026354964,0.0006217986,0.055879246],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.8138182,0.08749231,0.014153021,0.0051004305,0.076390445,0.003045561],"domain_scores_gemma":[0.8548957,0.056062616,0.014845449,0.009207921,0.061971426,0.0030167478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.11337656,0.00134259,0.0018392367,0.004764536,0.0024170554,0.009836876,0.005188024,0.022187203,0.0033955907],"category_scores_gemma":[0.13911131,0.00081469025,0.0033201848,0.0025360738,0.0069371103,0.004803856,0.002877118,0.00841897,0.0021260616],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000913584,0.00063989643,0.0050884415,0.0059392713,0.00039239082,0.0018646776,0.0018742088,0.0042602476,0.035186317,0.33460414,0.17137305,0.4378637],"study_design_scores_gemma":[0.00025759725,0.0016795767,0.007955804,0.0070943534,0.00035374827,0.0018716174,0.00086512545,0.0036922335,0.016094165,0.057198856,0.90274626,0.00019061878],"about_ca_topic_score_codex":0.0033847354,"about_ca_topic_score_gemma":0.0025578095,"teacher_disagreement_score":0.11337656,"about_ca_system_score_codex":0.0041711535,"about_ca_system_score_gemma":0.018495657,"threshold_uncertainty_score":0.5995997},"labels":[],"label_agreement":null},{"id":"W2525897054","doi":"","title":"Some statistical issues on the evaluation of the similarity and interchangeability of biologics","year":2013,"lang":"en","type":"article","venue":"Journal of Bioequivalence & Bioavailability","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Interchangeability; Biosimilar; Bioequivalence; Risk analysis (engineering); Biochemical engineering; Computer science; Pharmacology; Biotechnology; Computational biology; Business; Medicine; Engineering; Pharmacokinetics; Biology","score_opus":0.10810246180928541,"score_gpt":0.357205385288697,"score_spread":0.2491029234794116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525897054","genre_codex":"methods","genre_gemma":"methods","domain_codex":"methods","domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024783554,0.01427174,0.92992646,0.01595378,0.0023129547,0.0021117122,0.00051271654,0.0004872154,0.009639922],"genre_scores_gemma":[0.33896765,0.0043327576,0.6283835,0.012802591,0.005693427,0.006205812,0.0006660547,0.00055289594,0.0023952224],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.31088445,0.5986769,0.025580853,0.010908468,0.052543323,0.0014060268],"domain_scores_gemma":[0.061277483,0.8891921,0.013278565,0.024191521,0.011487992,0.00057225977],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.4677377,0.0018524448,0.0035048653,0.0059687905,0.0024046265,0.0056842086,0.0055524413,0.0054476443,0.0033293134],"category_scores_gemma":[0.7197635,0.0011236875,0.0071838875,0.008175802,0.02066034,0.0055086,0.0045302594,0.009226489,0.0005371847],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044388906,0.00073456485,0.039848745,0.0058372356,0.0052744183,0.002463594,0.0038814887,0.028138246,0.0058229575,0.452912,0.018870769,0.43177706],"study_design_scores_gemma":[0.00090922444,0.010030264,0.043044798,0.0035274571,0.002832073,0.004147843,0.0021440883,0.11735115,0.018611835,0.7223895,0.074255995,0.00075583113],"about_ca_topic_score_codex":0.0018325034,"about_ca_topic_score_gemma":0.0011994541,"teacher_disagreement_score":0.4677377,"about_ca_system_score_codex":0.0041265623,"about_ca_system_score_gemma":0.0033200206,"threshold_uncertainty_score":0.65637416},"labels":[],"label_agreement":null},{"id":"W2531190671","doi":"","title":"Free radical scavenging activity of the Malaysian Leech Saliva extract, Hirudinaria manillensis","year":2013,"lang":"en","type":"article","venue":"Journal of Bioequivalence & Bioavailability","topic":"Leech Biology and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Leech; Pharmacy; Traditional medicine; Lozenge; Medicine; Chemistry; Family medicine; Geography; Archaeology; World Wide Web","score_opus":0.019803026557157863,"score_gpt":0.26831410078046747,"score_spread":0.2485110742233096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531190671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840402,0.013178514,0.0006722988,0.0002636121,0.000081693295,0.00006675979,0.00020078513,0.00003059385,0.0014656135],"genre_scores_gemma":[0.99208766,0.0038430777,0.0012635345,0.00017879574,0.00006205922,0.000024651856,0.0002727641,0.0000041495,0.0022633155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991477,0.000021657856,0.000008885264,0.000010336302,0.000032718795,0.000011670697],"domain_scores_gemma":[0.9999149,0.000019364015,0.000019066407,0.00000535338,0.000025165758,0.00001622552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022197654,0.0003605074,0.0003358017,0.00038438276,0.00021151516,0.00022737634,0.00013904562,0.00027692117,0.0014948543],"category_scores_gemma":[0.0001956025,0.000117388314,0.0003074428,0.00021065315,0.00013443526,0.00021931696,0.00023022755,0.00036344814,0.00017477515],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028042536,0.00016786103,0.0005391242,0.0002764224,0.00002321975,0.000107104315,0.00004934051,0.000054235912,0.9867714,0.00005746352,0.00011681166,0.011556538],"study_design_scores_gemma":[0.00017521248,0.010512267,0.03951388,0.00008854965,0.00036487583,0.0011806411,0.00029101953,0.0006275575,0.93939716,0.0001388904,0.0076662214,0.000043662687],"about_ca_topic_score_codex":0.00079202873,"about_ca_topic_score_gemma":0.0012870469,"teacher_disagreement_score":0.0014948543,"about_ca_system_score_codex":0.000094645744,"about_ca_system_score_gemma":0.00022273278,"threshold_uncertainty_score":0.00500077},"labels":[],"label_agreement":null},{"id":"W2537045987","doi":"10.4172/jbb.1000250","title":"Designing, Development and Formulation of Mouth Disintegrating Telmisartan Tablet with Extended Release Profile Using Response Surface Methodology","year":2015,"lang":"en","type":"article","venue":"Journal of Bioequivalence & Bioavailability","topic":"Drug Solubulity and Delivery Systems","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Drug Research and Development","funders":"","keywords":"Telmisartan; Pharmacology; Response surface methodology; Computer science; Biochemical engineering; Medicine; Biomedical engineering; Engineering; Machine learning; Internal medicine","score_opus":0.35084446584383233,"score_gpt":0.4503953101799497,"score_spread":0.09955084433611738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2537045987","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.876871,0.007912708,0.1087822,0.00048012278,0.00009459242,0.00061488367,0.00053788617,0.00037025902,0.0043363734],"genre_scores_gemma":[0.88298273,0.006038831,0.10243396,0.00018325877,0.00003455917,0.0005057597,0.000576923,0.0000703017,0.007173694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999729,0.00003765645,0.000024332689,0.00005169557,0.00012700123,0.00003025674],"domain_scores_gemma":[0.9998982,0.000021036218,0.000031533025,0.0000077831555,0.00003065592,0.000010810954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037503886,0.00028707818,0.00036920965,0.000277142,0.00010584228,0.00037180592,0.00025882712,0.00039659522,0.00085773604],"category_scores_gemma":[0.0002756794,0.0001668396,0.0004889649,0.00022564299,0.00012603408,0.00033789052,0.00014121152,0.0004702617,0.00031453272],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055415625,0.00006513411,0.00013839017,0.00016672518,0.00001024869,0.0001070031,0.000026997659,0.00048265117,0.9886502,0.00010435813,0.00006849811,0.010124379],"study_design_scores_gemma":[0.000039378832,0.0020636918,0.0025578344,0.000012512638,0.000039322615,0.00040221217,0.000043843913,0.0058653755,0.98406315,0.000061063474,0.004827041,0.000024538846],"about_ca_topic_score_codex":0.00034568514,"about_ca_topic_score_gemma":0.0005803624,"teacher_disagreement_score":0.00085773604,"about_ca_system_score_codex":0.00015300508,"about_ca_system_score_gemma":0.00020634141,"threshold_uncertainty_score":0.0028694272},"labels":[],"label_agreement":null},{"id":"W4235998499","doi":"10.4172/jbb","title":"Journal of Bioequivalence & Bioavailability","year":2018,"lang":"fr","type":"paratext","venue":"Journal of Bioequivalence & Bioavailability","topic":"Biotechnology and Related Fields","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Fonds de recherche du Québec – Nature et technologies; Natural Sciences and Engineering Research Council of Canada","keywords":"Bioequivalence; Bioavailability; Pharmacology; Computational biology; Medicine; Computer science; Biology","score_opus":0.035405234836189715,"score_gpt":0.3246727591486874,"score_spread":0.28926752431249764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235998499","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033026155,0.16117778,0.10836297,0.020292265,0.007147899,0.0016069924,0.0051977905,0.0008665785,0.66232157],"genre_scores_gemma":[0.45958155,0.12446627,0.0811077,0.0026451235,0.0077096024,0.001634192,0.0043755732,0.00065604656,0.31782392],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965042,0.0009570896,0.00033003377,0.00023783278,0.0018836895,0.00008720082],"domain_scores_gemma":[0.99587727,0.0017574345,0.0005829247,0.00037766152,0.0012650752,0.00013968673],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0045234645,0.00061851385,0.0008603885,0.0026370212,0.00059037184,0.0031965098,0.00057770725,0.0015317416,0.039012544],"category_scores_gemma":[0.010591245,0.00020315251,0.00038318144,0.0024163947,0.0013257212,0.0014957765,0.00095021474,0.001463574,0.013324152],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060592155,0.0005100629,0.0019239571,0.0020647722,0.00010452421,0.00022608234,0.00020244099,0.0021685832,0.015715186,0.08079276,0.084803,0.81088275],"study_design_scores_gemma":[0.00012165778,0.0011049694,0.011700194,0.0008246097,0.000117728574,0.0011900817,0.00013407713,0.0071460046,0.018560395,0.050173037,0.90886545,0.00006189588],"about_ca_topic_score_codex":0.0010883501,"about_ca_topic_score_gemma":0.0008649905,"teacher_disagreement_score":0.96098745,"about_ca_system_score_codex":0.0012880714,"about_ca_system_score_gemma":0.0020555395,"threshold_uncertainty_score":0.13050997},"labels":[],"label_agreement":null}]}